News
After Loomer targeted surgeon general nominee and Kennedy ally Casey Means, Means’s brother, Calley, suggested that Loomer’s ...
7h
Clinical Trials Arena on MSNHansa’s Idefirix shows potential as pre-treatment to ElevidysHansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with ...
The cost of high-end, breakthrough medications traumatizes patients and their families. According to USAfacts, “national ...
9h
Zacks Investment Research on MSNSarepta to Report Q2 Earnings: What's in Store for the Stock?We expect Sarepta Therapeutics SRPT to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s ...
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...
Exploring the impact and challenges of the 'Right to Try' legislation for experimental treatments.
I understand the heartbreak of watching someone you love spiral. But compassion cannot mean locking people up,” writes a STAT ...
The FDA has denied that it plans to combine the Center for Drug Evaluation and Research and Center for Biologics Evaluation ...
Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Vinay Prasad was supposed to be the guy who kept Big Pharma in check. Now he’s gone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results